ASX-listed clinical-stage oncology company, PharmAust, has achieved a further annual extension to its current contract with the Drugs for Neglected Diseases initiative, or “DNDi”. The extension marks the 13th year that PharmAust’s wholly-owned subsidiary, Epichem, has been engaged by DNDi. The contract is expected to generate up to $1.02 million in revenue during 2021.